Ion Beams Application (IBA) has signed three new contracts to install and maintain three “Proteus One” proton therapy solutions for the treatment of cancer to the United Kingdom, IBA announced on Monday. IBA, a global medical technology company, is based in Louvain-la-Neuve, Belgium.
The cumulative value of the three contracts, signed with Proton Partners International (PPI), is estimated at about 105 million to 120 million euro.
“These centres will be IBA’s seventh, eighth and ninth installations for PPI”, IBA said in a press release. “To this day, IBA has sold 50 proton therapy centres worldwide, including 21 Proteus One single-room compact solutions.”
The three contracts are good news for the Walloonia-based company, whose shares, quoted on Euronext Brussels, had plummeted in early 2018 following the publication of a profit warning.
The announcement of the new contracts was welcomed on the Stock Exchange, with IBA shares moving up by at least 12% by mid-session on Monday.
IBA is scheduled to publish its annual results on 22 March.